Alterity Announces Presentation of Biomarker Data at the International Parkinson and Movement Disorder Society Congress 2021
- Written by PR Newswire
Study Results Successfully Inform the Design of ATH434 Phase 2 Clinical Trial
 |
MELBOURNE, Australia and SAN FRANCISCO, Sept. 20, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative...
